Funding for this research was provided by:
Cancer Research UK
Manchester Biomedical Research Centre
Received: 19 July 2020
Accepted: 24 March 2021
First Online: 1 April 2021
: This trial was performed with local ethics committee approval from the NRES Committee North West - Liverpool East, under the NHS Health Research Authority (11/NW/0118) [CitationRef removed]. Local research and development department approval was obtained and laboratory work was carried out in accordance with the principles of Good Clinical Laboratory Practice (World Health Organization 2009). All patients gave written informed consent to participate in the study.
: Not applicable.
: GJMP is a director and shareholder in Bioxydyn Limited, a company with an interest in advanced MRI biomarkers.No other competing interests